Antibe Therapeutics Inc. (OTCMKTS:ATBPD – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $0.22 and last traded at $0.22, with a volume of 0 shares changing hands. The stock had previously closed at $0.22.
Antibe Therapeutics Price Performance
The firm has a market capitalization of $83.44 million, a P/E ratio of -0.36 and a beta of 0.57. The stock has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.54.
About Antibe Therapeutics
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
See Also
- Five stocks we like better than Antibe Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Silicon Motion Proves That AI in Motion Stays in Motion
- ETF Screener: Uses and Step-by-Step Guide
- Undervalued UnitedHealth Group Won’t Be For Long
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
